side effects of taking too much semaglutide Overdose Risk: Safety Facts Semaglutide Dosing - Doctor's Advice

"As part of an extension trial published a year later, participants regained an average of two-thirds of the weight they shed within 12 months of discontinuing the drug." Within 12 months of discontinuing the drug, participants regained an average of two-thirds of the weight they shed

doi:10.1016/S2213-8587(19)30074-3 Holst JJ, Deacon CF

The Ideal You is Just a Call Away

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus (under the brand name Ozempic) and chronic weight management (Wegovy)

20 , 21 , 22 , 23 The aim of this review is to describe the study designs and clinical outcomes of the published trials from the STEP programme, discuss clinical implications of the data and practicalities of using semaglutide 2.4 mg in individuals with obesity and place the STEP programme into the context of the current and future obesity pharmacotherapy landscapes